DIRAS3 and non-small cell lung carcinoma: To further validate that DIRAS3 regulates the RAS/ERK pathway in NSCLC cells, we treated the cells with a 10 mM RAS/ERK pathway inhibitor PD901 in HCC827 cells following the silencing of DIRAS3 (Figure 5(c)).